Morningstar

Amorphical Announces First Patient Enrolled in Phase 2 Clinical Trial of Nano-Amorphous Mineral-Based Therapy in Stage IV Pancreatic Cancer Patients

NES ZIONA, Israel, Nov. 24, 2025 /PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced that the first patient has been ...
FOX8 Cleveland

Amorphical Appoints Eden Ben as CEO, as Company Advances Regulatory Pathway for Nano-Amorphous Mineral-Based Therapeutics

NES ZIONA, Israel, Sept. 2, 2025 /PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, announced today the appointment of Eden Ben as its ...
Morningstar

Amorphical Announces Positive Final Long-Term Results from Phase 2 Crohn's Disease Trial: Results Confirm Efficacy and Show Sustained Clinical Remission

NES ZIONA, Israel, Dec. 16, 2025 /PRNewswire/ -- Amorphical, a developer of nano-amorphous mineral-based pharmacologic agents, today announced positive final long-term follow-up data from its Phase 2 ...
MarketWatch

Amorphical to Present Long-Term Phase 2 Crohn's Disease Data at the 21st Congress of ECCO

The MarketWatch News Department was not involved in the creation of this content. Data Confirms 62.5% Sustained Clinical Remission at 48 Weeks, Highlighting the Potential of a Novel, ...